CXCR4 and acute myeloid leukemia: We previously demonstrated that CXCR4 is an important mediator of chemotherapy resistance in pediatric ALL and acute myeloid leukemia (AML), and that treatment with the FDA-approved CXCR4 inhibitor plerixafor could reverse stromal protection and chemotherapy resistance [8–10].